A small open-label study randomised 60 people on stable BIC/F/TAF to continue daily ART or switch to only taking treatment five days a week.
The same FOTO strategy (Five-On Two-Off) was studied over 15 years ago using Atripla, with all participants remaining undetectable over 52 weeks.
Even though low drug trough levels were reported in some people at some time points, viral suppression was maintained over 52 weeks.
Read the full report by Simon Collins, HIV i-Base here.
Source : HIV i-Base
Related HIV and Co-Infections News
-
Gilead’s investigational single-tablet regimen of bictegravir and lenacapavir for HIV treatment meets primary endpoint in Phase 3 ARTISTRY-2 trial
-
New data from EACS 2025 on quality of life and comorbidities in people with HIV
-
IDWeek 2025: Real-world findings show lenacapavir effective in highly treatment-experienced people with HIV
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.